Syndax Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Syndax Pharmaceuticals, Inc. (SNDX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $14.07M, a 1.19% increase year-over-year.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $12.19M, a 16.22% increase year-over-year.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $12.20M, a 2.25% increase year-over-year.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $13.90M, a 40.49% increase year-over-year.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $47.96M, a 11.47% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $43.03M, a 39.01% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $30.95M, a 93.21% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.02M, a 20.29% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $14.07M 10-Q · filed 2026-08-04 | $26.26M derived: sum of 2 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $12.19M 10-Q · filed 2026-08-04 | ||||
| 2025-12-31 | $47.96M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $12.20M 10-Q · filed 2025-11-03 | $26.11M derived: sum of 2 quarters · filed 2026-08-04 | $36.59M derived: sum of 3 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $13.90M 10-Q · filed 2026-08-04 | $24.39M derived: sum of 2 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $10.49M 10-Q · filed 2026-08-04 | ||||
| 2024-12-31 | $43.03M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $11.93M 10-Q · filed 2025-11-03 | $21.83M derived: sum of 2 quarters · filed 2025-11-03 | $30.73M derived: sum of 3 quarters · filed 2025-11-03 | ||
| 2024-06-30 | $9.90M 10-Q · filed 2025-11-03 | $18.80M derived: sum of 2 quarters · filed 2025-11-03 | |||
| 2024-03-31 | $8.90M 10-Q · filed 2025-11-03 | ||||
| 2023-12-31 | $30.95M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $8.32M 10-Q · filed 2024-11-05 | $16.39M derived: sum of 2 quarters · filed 2024-11-05 | $22.62M derived: sum of 3 quarters · filed 2024-11-05 | ||
| 2023-06-30 | $8.06M 10-Q · filed 2024-11-05 | $14.30M derived: sum of 2 quarters · filed 2024-11-05 | |||
| 2023-03-31 | $6.24M 10-Q · filed 2024-11-05 | ||||
| 2022-12-31 | $16.02M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $4.36M 10-Q · filed 2023-11-02 | $8.30M derived: sum of 2 quarters · filed 2023-11-02 | $11.78M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $3.94M 10-Q · filed 2023-11-02 | $3.94K 10-Q · filed 2022-08-08 | $7.42M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $3.48M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $13.32M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $3.38M 10-Q · filed 2022-11-03 | $6.62M derived: sum of 2 quarters · filed 2022-11-03 | $9.39M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $3.24M 10-Q · filed 2022-11-03 | $6.01M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $2.77M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $9.06M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $3.06M 10-Q · filed 2021-11-15 | $5.19M derived: sum of 2 quarters · filed 2021-11-15 | $7.02M derived: sum of 3 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $2.13M 10-Q · filed 2021-11-15 | $3.96M derived: sum of 2 quarters · filed 2021-11-15 | |||
| 2020-03-31 | $1.83M 10-Q · filed 2021-11-15 | ||||
| 2019-12-31 | $6.00M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $1.55M 10-Q · filed 2020-11-05 | $2.89M derived: sum of 2 quarters · filed 2020-11-05 | $4.48M derived: sum of 3 quarters · filed 2020-11-05 | $5.95M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-06-30 | $1.34M 10-Q · filed 2020-11-05 | $2.93M derived: sum of 2 quarters · filed 2020-11-05 | $4.40M derived: sum of 3 quarters · filed 2021-03-12 | $6.14M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-03-31 | $1.59M 10-Q · filed 2020-11-05 | $3.06M derived: sum of 2 quarters · filed 2021-03-12 | $4.80M derived: sum of 3 quarters · filed 2021-03-12 | $6.37M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2018-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $3.21M derived: sum of 2 quarters · filed 2021-03-12 | $4.78M derived: sum of 3 quarters · filed 2021-03-12 | $6.20M 10-K · filed 2021-03-12 | |
| 2018-09-30 | $1.74M 10-Q · filed 2019-11-07 | $3.31M derived: sum of 2 quarters · filed 2019-11-07 | $4.73M 10-Q · filed 2018-11-05 | $6.01M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-06-30 | $1.57M 10-Q · filed 2019-11-07 | $2.99M 10-Q · filed 2018-08-08 | $4.27M derived: sum of 3 quarters · filed 2020-03-05 | $5.62M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-03-31 | $1.42M 10-Q · filed 2019-11-07 | $2.70M derived: sum of 2 quarters · filed 2020-03-05 | $4.05M derived: sum of 3 quarters · filed 2020-03-05 | ||
| 2017-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $2.63M derived: sum of 2 quarters · filed 2020-03-05 | $5.45M 10-K · filed 2020-03-05 | ||
| 2017-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $4.17M 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $2.83M 10-Q · filed 2017-08-10 | ||||
| 2016-12-31 | $947.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.74M derived: sum of 2 quarters · filed 2019-03-07 | $2.52M derived: sum of 3 quarters · filed 2019-03-07 | $4.71M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $792.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.57M derived: sum of 2 quarters · filed 2016-11-14 | $3.76M 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | $779.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $2.97M 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | $2.19M 10-Q · filed 2016-05-16 | ||||
| 2015-12-31 | $3.88M 10-K · filed 2018-03-08 | ||||
| 2014-12-31 | $2.26M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |